COVID-19 Treatment: The Race Against Time
Open accessAbstract
The new outbreak of the novel coronavirus infection emerged in Wuhan- China in late 2019, by the end of Mar 2020, it has spread in more than 178 countries and territories. There is no vaccine or antiviral treatment for COVID-19. Currently, there are several drugs and vaccines being tested for their potential activity against the disease. In this review, we briefly discuss some of the investigational drugs and vaccines being tested against COVID-19 as well as their potential drawbacks.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
During COVID-19 there are many grounded research in biomedical area yet not in mental health.
“During COVID-19 there are many grounded research (16) in biomedical area yet not in mental health.”
From A proposed framework based on literature review of online contextual mental health services to enhance wellbeing and address psychopathology during covid-19 (2020) · cites this paper as [16]
The Introduction (p. 1) reports an increasing number of COVID-19 treatment and vaccine trials, including 60 active and recruiting trials as of March 31, 2020. This supports substantial biomedical research, but the paper does not assess mental-health research or compare the two fields. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286 · see citing works
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923 · see citing works
Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
Russell, C. D., Millar, J. E., & Baillie, J. K. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30317-2 · Cited by 2,016 · see citing works
Shimabukuro‐Vornhagen, A., Gödel, P., Subklewe, M. S., Stemmler, H., Schlößer, H., Schlaak, M. S., Kochanek, M., Böll, B., & von Bergwelt‐Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,673 · see citing works
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,637 · see citing works
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Mbaya, O. T., Proschan, M. A., Mukadi‐Bamuleka, D., Lusakibanza, M. M., Nzolo, D. B., Tshomba, A. O., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,617 · see citing works
Maini, R. N., Taylor, P. C., Szechinski, J., Pavelka, K., Bröll, J., Balint, G., Emery, P., Raemen, F., Petersen, J., Smolen, J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22033 · Cited by 790 · see citing works
Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Tchesnokov, E. P., Feng, J. Y., Porter, D., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 623 · see citing works
Zeldin, R. K. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh029 · Cited by 317 · see citing works
New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections
Clercq, E. D. (2019) · Chemistry - An Asian Journal · doi:10.1002/asia.201900841 · Cited by 217 · see citing works
Tocilizumab: The first interleukin-6-receptor inhibitor
Sebba, A. I. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070449 · Cited by 214 · see citing works
Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers
Park, S. Y., Lee, J. S., Son, J. S., Ko, J. H., Peck, K. R., Jung, Y., Woo, H., Joo, Y., Eom, J. S., & Shi, H. (2018) · Journal of Hospital Infection · doi:10.1016/j.jhin.2018.09.005 · Cited by 78 · see citing works
Hydroxychloroquine-induced cardiomyopathy and heart failure in twins
Zhao, H., Wald, J. W., Palmer, M., & Han, Y. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.66 · Cited by 35 · see citing works
Vityala, Y. (2020) · International Journal of Research in Pharmaceutical Sciences · doi:10.26452/ijrps.v11ispl1.1973 · Cited by 26 · see citing works
Continuous regional application of protease inhibitor in the treatment of acute pancreatitis
Yamauchi, J.-I., Takeda, K., Shibuya, K., Sunamura, M., & Matsuno, S. (2001) · Pancreatology · doi:10.1159/000055878 · Cited by 21 · see citing works
Chloroquine and COVID-19: A Light at the End of the Tunnel, or is it Another Train?
Aljofan, M., & Gaipov, A. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/7863 · Cited by 13 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [2]2. Zhao H, Wald J, Palmer M, Han Y. Hydroxychloroquineinduced cardiomyopathy and heart failure in twins. Journal of thoracic disease. 2018;10(1):E70. https://doi.org/10. 21037/JTD.2017.12.66 PMID:29600108 PMCID:PMC5863196
Cited by
Sorted by citations
Tanhan, A., Yavuz, K. F., Young, J. S., Nalbant, A., Arslan, G., Yıldırım, M., Ulusoy, S., Genç, E., Uğur, E., & Çiçek, İ. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/8316 · Cited by 104 · see citing works
A Generalized Overview of SARS-CoV-2: Where Does the Current Knowledge Stand?
Ullah, M. A., Islam, H., Rahman, A., Masud, J., Shweta, D. S., Araf, Y., Sium, S. M. A., & Sarkar, B. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/8258 · Cited by 26 · see citing works
Pouya, M. A., Afshani, S. M., Maghsoudi, A. S., Hassani, S., & Mirnia, K. (2020) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-020-00359-4 · Cited by 19 · see citing works
Education in Online Environment from Students’ and Teachers’ Perspective
Blahušiaková, M., Mokošová, D., & Šoltés, E. (2021) · International Journal of Cognitive Research in Science Engineering and Education · doi:10.23947/2334-8496-2021-9-2-203-226 · Cited by 17 · see citing works
COVID-19 Outbreak in Post-Soviet States: Modeling the Best and Worst Possible Scenarios
Issanov, A., Amanbek, Y., Abbay, A., Adambekov, S., Aljofan, M., Kashkynbayev, A., & Gaipov, A. (2020) · Electronic Journal of General Medicine · doi:10.29333/ejgm/8346 · Cited by 13 · see citing works
Self-citationReview of pharmacologic and immunologic agents in the management of COVID-19
Ungogo, M. A., Mohammed, M., Umar, B. N., Bala, A. A., & Khalid, G. M. (2021) · Biosafety and Health · doi:10.1016/j.bsheal.2021.01.001 · Cited by 13 · see citing works
Epdemiology of coronavirus disease 2020 (COVID-19) in Algeria
Lounis, M. (2020) · New Microbes and New Infections · doi:10.1016/j.nmni.2020.100822 · Cited by 12 · see citing works
COVID-19 Outbreak in Kazakhstan: Current Status and Challenges
Zhalmagambetov, B., Madikenova, M., Paizullayeva, S., Abbay, A., & Gaipov, A. (2020) · Journal of Clinical Medicine of Kazakhstan · doi:10.23950/1812-2892-jcmk-00763 · Cited by 12 · see citing works
Self-citationKumar, A., Sharma, A., Tirpude, N. V., Thakur, S., & Kumar, S. (2021) · Current Molecular Medicine · doi:10.2174/1566524021666210803154250 · Cited by 9 · see citing works
Dakhil, Z. A., & Farhan, H. A. (2020) · Journal of Clinical and Experimental Investigations · doi:10.5799/jcei/7941 · Cited by 7 · see citing works
Combating COVID-19 Pandemic in Bangladesh: A Memorandum from Developing CountryPreprint
Moin, A. T., Sakib, M. N., Araf, Y., Sarkar, B., & Ullah, M. A. (2020) · Preprints.org · doi:10.20944/preprints202005.0435.v1 · Cited by 7 · see citing works
Emerging Pharmaceutical Treatments of Novel COVID-19: A Review
Hussain, A. R., Kaler, J., & Dubey, A. K. (2020) · Cureus · doi:10.7759/cureus.8260 · Cited by 5 · see citing works
Potential Compounds for the Inhibition of TMPRSS2Preprint
Roomi, M., & Khan, Y. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12727787.v1 · Cited by 5 · see citing works
Can Human Transmit COVID-19 to Animal?
Baz, S. E., & Imziln, B. (2020) · Journal of Clinical and Experimental Investigations · doi:10.5799/jcei/8262 · Cited by 4 · see citing works
Forecasting COVID-19 in Morocco
Layelmam, M., Laaziz, Y. A., Benchelha, S., Diyer, Y., & Rarhibou, S. (2020) · Journal of Clinical and Experimental Investigations · doi:10.5799/jcei/8264 · Cited by 4 · see citing works
Potential Compounds for the Inhibition of TMPRSS2Preprint
Roomi, M., & Khan, Y. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12727787 · Cited by 4 · see citing works
"Repurposing of Heterocyclic Compounds as Anti- COVID-19 (SARS-Cov-2) Therapeutics: A Review"
Kumar, R. (2021) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2021.38.006195 · Cited by 2 · see citing works
Benramache, S., & Bougherara, H. (2020) · Journal of Clinical and Experimental Investigations · doi:10.5799/jcei/8263 · Cited by 2 · see citing works
Combating COVID-19 Pandemic in Bangladesh: A Memorandum from Developing Country
Ullah, M. A., Moin, A. T., Sakib, M. N., Araf, Y., & Sarkar, B. (2020) · European Journal of Medical and Educational Technologies · doi:10.30935/ejmets/8571 · Cited by 2 · see citing works
Identifying Therapeutic Compounds Targeting RNA-Dependent-RNA-Polymerase of Sars-Cov-2Preprint
Roomi, M., Mahmood, M., & Khan, Y. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12477761.v1 · Cited by 2 · see citing works
Identifying Therapeutic Compounds Targeting RNA-Dependent-RNA-Polymerase of Sars-Cov-2Preprint
Roomi, M., Mahmood, M., & Khan, Y. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12477761 · Cited by 2 · see citing works
Identifying Therapeutic Compounds Targeting RNA-Dependent-RNA-Polymerase of Sars-Cov-2Preprint
Roomi, M., Mahmood, M., & Khan, Y. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12477761.v3 · Cited by 1 · see citing works
Phylogenetic analyses and genomic variation of the 2019-nCoV
Haq, F. U., Saleem, S., Imran, M., Ghazal, A., Ahmad, K. A., Roman, M., & Rahman, S. U. (2020) · Journal of Pharmaceutical and Biopharmaceutical Research · doi:10.25082/jpbr.2020.01.004
An Insight into Pandemic COVID-19: Structure, Epidemiology and Therapeutics
Ajmera, S., Ranjitha, H. B., Divya, A., Dasyam, J., & Merugu, R. (2020) · Current Biotechnology · doi:10.2174/2211550109999201211203631
Identifying Therapeutic Compounds Targeting RNA-Dependent-RNA-Polymerase of Sars-Cov-2Preprint
Roomi, M., Mahmood, M., & Khan, Y. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12477761.v4
Identifying Therapeutic Compounds Targeting RNA-Dependent-RNA-Polymerase of Sars-Cov-2Preprint
Roomi, M., Mahmood, M., & Khan, Y. D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12477761.v2
- Authors
- Aljofan, M., & Gaipov, A.
- Affiliations
- Nazarbayev University (KZ)
- Corresponding author
- Aljofan, Mohamad
- Venue
- Electronic Journal of General Medicine
- Publisher
- Modestum Publishing Ltd
- Published
- 2020-04-05
- Volume
- 17
- Issue
- 6
- Pages
- em227
- ISSN
- 2516-3507 (ISSN-L)
- OpenAlex
- W3015018172
- Cited by
- 27
- References
- 16
- Citations by year
- 2021: 5 · 2020: 22
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Electronic Journal of General Medicine (publishedVersion, cc-by)
- Nazarbayev University Repository (Nazarbayev University) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Keywords
- COVID-19 pandemic, SARS-CoV-2, antiviral agents, investigational drugs, COVID-19 vaccines, drug development, vaccine development
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
